Walleye Capital’s Relmada Therapeutics RLMD Stock Holding History

Walleye Capital’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-200	Closed	-$7K	–	3560
2022 Q3	$7K	Buy	+200	New	+$5.54K	﹤0.01%	2874

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Walleye Capital's RLMD Position: Q2 2023 in Review

Walleye Capital sold out of Relmada Therapeutics (RLMD) in Q2 2023, closing a stake of 262,481 shares — an estimated $593K sold.

Walleye Capital first reported a position in RLMD in Q4 2021 and held it in 5 quarters. The position peaked at $3.33M in Q1 2022. 95 funds tracked by Wall St. Rank hold RLMD as of Q2 2023.

Walleye Capital reported no remaining Relmada Therapeutics position as of Q2 2023 after selling out during the quarter.
Walleye Capital sold 262,481 Relmada Therapeutics shares in Q2 2023, an estimated $593K.
Walleye Capital first reported a position in Relmada Therapeutics in Q4 2021 and held it in 5 quarters.
Walleye Capital's Relmada Therapeutics position peaked at $3.33M in Q1 2022.
95 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2023.

Based on Walleye Capital's 13F filing for Q2 2023, filed 14 Aug 2023.